Associated Papers
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
So JY et al.
Orphanet Journal of Rare Diseases, 2022
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Bornert O et al.
The Journal of Investigative Dermatology, 2021
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Eichstadt S et al.
Jci Insight, 2019
Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
Cutlar L et al.
Experimental Dermatology, 2014
Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.
Tolar J et al.
The Journal of Investigative Dermatology, 2011
Forty-two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort.
Kern JS et al.
The British Journal of Dermatology, 2009
Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
Dang N et al.
Experimental Dermatology, 2008
Expanding the COL7A1 mutation database: novel and recurrent mutations and unusual genotype-phenotype constellations in 41 patients with dystrophic epidermolysis bullosa.
Kern JS et al.
The Journal of Investigative Dermatology, 2006
Select a paper to view details